Journal article
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
Abstract
Combined MAPK/PI3K pathway inhibition represents an attractive, albeit toxic, therapeutic strategy in oncology. Since PTEN lies at the intersection of these two pathways, we investigated whether PTEN status determines the functional response to combined pathway inhibition. PTEN (gene, mRNA, and protein) status was extensively characterized in a panel of cancer cell lines and combined MEK/mTOR inhibition displayed highly synergistic …
Authors
Milella M; Falcone I; Conciatori F; Matteoni S; Sacconi A; De Luca T; Bazzichetto C; Corbo V; Simbolo M; Sperduti I
Journal
Scientific Reports, Vol. 7, No. 1,
Publisher
Springer Nature
DOI
10.1038/srep43013
ISSN
2045-2322
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AnimalsCell Line, TumorDrug SynergismEverolimusFemaleHumansJanus Kinase 1MAP Kinase Kinase KinasesMiceMice, NudeNeoplastic Stem CellsPTEN PhosphohydrolasePhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPyridonesPyrimidinonesRNA InterferenceRNA, Small InterferingSTAT3 Transcription FactorTOR Serine-Threonine Kinases